# ASTHMA

## 定義 and 流行病學 (_Lancet_ 2018;391:783)

• Chronic inflam disorder with **airway hyperresponsiveness** + **variable airflow obstruction**

• Affects 5–10% population; ~85% of cases by age 40 y

## 臨床表現 (_NEJM_ 2013;369:549)

• Classic triad = **wheezing**, **cough, dyspnea;** others include chest tightness, sputum; symptoms typically _chronic_ with _episodic exacerbation_

• Precipitants (**triggers**)

_respiratory irritants_ (smoke, perfume, etc.) & _allergens_ (pets, dust mites, pollen, etc.)

_infections_ (URI, bronchitis, sinusitis)

_drugs_ (eg, ASA & NSAIDs via leukotrienes, βB via bronchospasm, MSO4 via histamine)

emotional stress, cold air, exercise (increase in ventilation dries out airways)

## Physical examination

• Wheezing and prolonged expiratory phase

• Presence of nasal polyps, rhinitis, rash → _allergic component_

• Exacerbation → ↑ RR, ↑ HR, accessory muscle use, diaphoresis, pulsus paradoxus

Diagnostic studies (_JAMA_ 2017;318:279)

• **Spirometry:** ↓ FEV1, ↓ FEV1/FVC, coved flow-volume loop; lung volumes: ± ↑ RV & TLC

⊕ bronchodilator response (↑ FEV1 ≥12% & ≥200 mL) strongly suggestive of asthma

methacholine challenge (↓ FEV1 ≥20%) if 肺功能 正常: Se >90%

• Allergy suspected → consider checking serum IgE, eos, skin testing/RAST

## Ddx (“all that wheezes is not asthma…”)

• Hyperventilation & panic attacks

• Upper airway obstruction or inh foreign body; laryngeal/vocal cord dysfxn (eg, 2° to GERD)

• CHF (“cardiac asthma”); COPD; bronchiectasis; ILD (including sarcoidosis); vasculitis; PE

## “Asthma plus” syndromes

• Atopy = asthma + allergic rhinitis + atopic dermatitis

• Aspirin-exacerbated respiratory disease (Samter’s syndrome) = asthma + ASA sensitivity + nasal polyps (_J Allergy Clin Immunol_ 2015;135:676)

• ABPA = asthma + pulmonary infiltrates + allergic rxn to _Aspergillus_ (_Chest_ 2009;135:805)

### Dx: ↑ IgE to _Asperg._ & total (>1000), ↑ _Asperg._ IgG levels, ↑ eos, central bronchiectasis

### Rx: steroids ± itra-/voriconazole for refractory cases (_NEJM_ 2000;342:756)

• Eosinophilic granulomatosis with polyangiitis (EGPA, previously Churg-Strauss) = asthma + eosinophilia + granulomatous vasculitis

# CHRONIC MANAGEMENT

“Reliever” medications (used prn to quickly relieve sx)

• _Short-acting_ inh β**2****\-agonists** (SABA): albuterol Rx of choice

• _Short-acting_ inh **anticholinergics** (ipratropium) ↑ β2\-agonist delivery → ↑ bronchodilation

“Controller” meds (taken daily to keep control) (_JAMA_ 2017;318:279)

• Inh **corticosteroids** (ICS) Rx of choice. Superior to LAMA if sputum with ≥2% eos (_NEJM_ 2019;380:2009). PO steroids may be needed for severely uncontrolled asthma; avoid if possible b/c of systemic side effects.

• _Long-acting_ inh β**2****\-agonists** (LABA; eg, salmeterol) safe & ↓ exacerbations when added to ICS (_NEJM_ 2018;378:2497)

• _Long-acting_ inh **antimuscarinics** (LAMA; eg, tiotropium, umeclidinium): may consider if sx despite ICS+LABA (_JAMA_ 2018;319:1473)

• **Leukotriene receptor antagonists** (LTRA): some 病人 very responsive, esp. ASA-sens (_AJRCCM_ 2002;165:9) and exercise-induced (_Annals_ 2000;132:97). May be noninferior to ICS initial Rx and LABA add-on Rx (_NEJM_ 2011;364:1695).

• **Nedocromil/cromolyn**: limited use in adults. Useful in young 病人, exercise-induced bronchospasm; ineffective unless used before trigger or exercise exposure.

## Immunotherapies (_NEJM_ 2017;377:965)

• Allergen ImmunoRx (“allergy shots”) may help if sig. allerg. component (_JAMA_ 2016;315:1715)

• **Anti-IgE** (omalizumab) for uncontrolled mod-to-severe allergic asthma (w/ IgE >30) on ICS ± LABA (_JAMA_ 2017; 318:279)

• Anti-IL5 (mepolizumab, reslizumab) ↓ exacerb in severe asthma (_NEJM_ 2014;371:1189 & 1198)

• Anti-IL5Rα (benralizumab) ↓ steroid use, ↓ exac. in sev asthma with eos (_NEJM_ 2017;376:2448)

• Anti-IL4Rα (dupilumab) blocks IL-4 & IL-13; ↓ exacerb in severe asthma, ↓ steroid use, ↑ FEV1 (_NEJM_ 2018;378:2475 & 2486)

## Principles of 治療

• Education and avoidance of environmental triggers (_Lancet_ 2015;386:1075); yearly flu shot

• Use quick-relief rescue medication as needed for all 病人

• Goal to achieve **complete control** = daily sx ≤2/wk, ∅ nocturnal sx or limitation of activity, reliever med ≤2/wk, 正常 peak expiratory flow rate or FEV1; partly controlled = 1–2 of the above present in a wk; uncontrolled = ≥3 of the above present in a wk

• Step up 治療 as needed to gain control, step down as tolerated

• Can abort exacerb by quadrupling ICS if deteriorating control (_NEJM_ 2018;378:902)

![](https://i.imgur.com/cU10cEg.jpg)

# EXACERBATION

## Evaluation

• History: baseline PEF, steroid requirement, ED visits, hospital admissions, prior intubation

Current exacerbation: duration, severity, potential precipitants, meds used

_Risk factors for life-threatening:_ prior intubation, h/o near-fatal asthma, ED visit/hosp for asthma within 1 y, current/recent PO steroids, not using ICS, overdependent on SABA, Ψ, h/o noncompliance

• Physical exam: VS, pulm, accessory muscle use, pulsus paradoxus, abdominal paradox

Assess for barotrauma: asymmetric breath sounds, tracheal deviation, subcutaneous air → pneumothorax, precordial (Hamman’s) crunch → pneumomediastinum

• Diagnostic studies: **peak expiratory flow** (know personal best; <80% personal best c/w poor control, <50% c/w severe exacerbation); **S****a****O****2**; **CXR** to 排除 PNA or PTX; ABG if severe (low PaCO2 initially; 正常 or high PaCO2 _may_ signify tiring)

![](https://i.imgur.com/zu71CQt.jpg)

**_Resp arrest imminent_:** drowsy, abdominal paradox, wheezes inaudible (b/c ∅ air movement), bradycardia, loss of abdominal paradox (respiratory muscle fatigue). Presence of several parameters (not necessarily all) indicates classification (adapted from GINA 2019 update).

## Initial 治療 (_NEJM_ 2010;363:755)

• **Oxygen** to keep SaO2 ≥90%

• **Inhaled SABA** (eg, albuterol) by MDI (4–8 puffs) or nebulizer (2.5–5 mg) q20min

• **Corticosteroids:** prednisone 40-60 mg PO if outPt; methylpred IV if ED or inPt

• **Ipratropium** MDI (4–6 puffs) or nebulizer (0.5 mg) q20min if severe (_Chest_ 2002;121:1977)

• _Reassess after 60–90 min of Rx_

Mild-mod exacerbation: cont SABA q1h

Sev exacerbation: SABA & ipratropium q1h or cont.; if refractory, consider Mg ± heliox

• _Decide disposition within 4 h of presentation and after 1–3 h of Rx_

### Figure 2-2 Disposition of patients after initial 治療 of asthma exacerbation

![](https://i.imgur.com/Jb0Sb8j.jpg)
ICU-level care

• **High-dose steroids:** methylpred 125 mg IV q6h (_NEJM_ 1999;340:1941)

• **Invasive ventilation:**

Large ET tube, Pplat <30 cm H2O (predicts barotrauma better than PIP), max exp time

PEEP individualized to patient physiology

Paralysis, inhalational anesthetics, bronchoalveolar lavage with mucolytic, heliox (60–80% helium) and ECMO have been used with success

• NPPV likely improves obstruction (_Chest_ 2003;123:1018), but controversial and rarely used
